Completed PHASE3 INTERVENTIONAL 2-arm NCT01759030

Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis (BIORA)

Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies

Sponsor: Biocad

Conditions Rheumatoid Arthritis

Interventions Rituximab

Updated 7 times since 2017 Last updated: Mar 24, 2017 Started: Dec 31, 2012 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Biocad and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Apr 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2017 — Apr 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biocad

Data source: Biocad

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmadābād, India , Aurangabad, India , Bangalore, India , Chelyabinsk, Russia , Chennai, India , Cuttack, India , Homyel, Belarus , Hyderabad, India , Jaipur, India , Kharkiv, Ukraine and 17 more locations